Previous 10 | Next 10 |
Image source: The Motley Fool. Simulations Plus, Inc. (NASDAQ: SLP) Q3 2022 Earnings Call Jul 06, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Simulations Plus, Inc. (SLP) Q3 2022 Earnings Call Transcript
Simulations Plus press release ( NASDAQ: SLP ): FQ3 GAAP EPS of $0.20 beats by $0.02 . Revenue of $14.96M (+17.1% Y/Y) beats by $0.63M . Software revenue increased 16% to $9.7 million, representing 64% of total revenue; Services revenue increased 19% to $5....
Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 11%; Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (Nasdaq: SLP), a lea...
Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports and conference presentat...
With Wall Street facing a holiday-shortened schedule, next week sees a sparse list of corporate earnings. Still, a number of international names will come into the spotlight, including reports from one of the UK’s largest grocery chains and one of Asia’s largest retailers....
Record-setting attendance for the global pharmacometrics community Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced record-setting attendance and virtual cont...
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to supp...
Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET Simulations Plus, Inc. (Nasdaq: SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the financial markets ...
DILIsym application contributes to approval of new drugs for migraine treatment Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it has published importa...
New 3D structure generation functionality and extensions to the HTPK Simulation Module among the many enhancements Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today ann...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...